Ruoxi Pi

Ruoxi Pi

Auto-generated profile, based on publicly available information

Ruoxi Pi

Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AWAaron J. Wilk
Aaron J. Wilk
MLMadeline Jane Lee
Madeline Jane Lee
BWBei Wei
Bei Wei
BPBenjamin Parks
Benjamin Parks
RPRuoxi Pi
Ruoxi Pi
CBCatherine A. Blish
Catherine A. Blish
Our understanding of protective versus pathological immune responses to SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is limited by inadequate profiling of patients at the extremes of the disease severity spectrum. Here, we performed multi-omic single-cell immune profiling of 64 COVID-19 patients across the full range of disease severity, from outpatients with mild disease to fatal cases. Our transcriptomic, epigenomic, and proteomic analyses revealed widespread dysfunction of peripheral innate immunity in severe and fatal COVID-19, including prominent hyperactivation signatures in neutrophils and NK cells. We also identified chromatin accessibility changes at NF-κB binding sites within cytokine gene loci as a potential mechanism for the striking lack of pro-inflammatory cytokine production observed in monocytes in severe and fatal COVID-19. We further demonstrated that emergency myelopoiesis is a prominent feature of fatal COVID-19. Collectively, our results reveal disease severity–associated immune phenotypes in COVID-19 and identify pathogenesis-associated pathways that are potential targets for therapeutic intervention.

1 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZLZhijian Li
Zhijian Li
LALaura Amaya
Laura Amaya
RPRuoxi Pi
Ruoxi Pi
SWSean K. Wang
Sean K. Wang
ARAlok Ranjan
Alok Ranjan
PWPaul A. Wender
Paul A. Wender
The introduction of more effective and selective mRNA delivery systems is required for the advancement of many emerging biomedical technologies including the development of prophylactic and therapeutic vaccines, immunotherapies for cancer and strategies for genome editing. While polymers and oligomers have served as promising mRNA delivery systems, their efficacy in hard-to-transfect cells such as primary T lymphocytes is often limited as is their cell and organ tropism. To address these problems, considerable attention has been placed on structural screening of various lipid and cation components of mRNA delivery systems. Here, we disclose a class of charge-altering releasable transporters (CARTs) that differ from previous CARTs based on their beta-amido carbonate backbone (bAC) and side chain spacing. These bAC-CARTs exhibit enhanced mRNA transfection in primary T lymphocytes in vitro and enhanced protein expression in vivo with highly selective spleen tropism, supporting their broader therapeutic use as effective polyanionic delivery systems.

8 February 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
AFAllan Feng
Allan Feng
EYEmily Y. Yang
Emily Y. Yang
AMAndrew Reese Moore
Andrew Reese Moore
SDShaurya Dhingra
Shaurya Dhingra
SCSarah Esther Chang
Sarah Esther Chang
PUPaul J. Utz
Paul J. Utz
The widespread presence of autoantibodies in acute infection with SARS-CoV-2 is increasingly recognized, but the prevalence of autoantibodies in non–SARS-CoV-2 infections and critical illness has not yet been reported. We profiled IgG autoantibodies in 267 patients from 5 independent cohorts with non–SARS-CoV-2 viral, bacterial, and noninfectious critical illness. Serum samples were screened using Luminex arrays that included 58 cytokines and 55 autoantigens, many of which are associated with connective tissue diseases (CTDs). Samples positive for anti-cytokine antibodies were tested for receptor blocking activity using cell-based functional assays. Anti-cytokine antibodies were identified in > 50% of patients across all 5 acutely ill cohorts. In critically ill patients, anti-cytokine antibodies were far more common in infected versus uninfected patients. In cell-based functional assays, 11 of 39 samples positive for select anti-cytokine antibodies displayed receptor blocking activity against surface receptors for Type I IFN, GM-CSF, and IL-6. Autoantibodies against CTD-associated autoantigens were also commonly observed, including newly detected antibodies that emerged in longitudinal samples. These findings demonstrate that anti-cytokine and autoantibodies are common across different viral and nonviral infections and range in severity of illness.

18 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
AWAaron J. Wilk
Aaron J. Wilk
MLMadeline Jane Lee
Madeline Jane Lee
BWBei Wei
Bei Wei
BPBenjamin Parks
Benjamin Parks
RPRuoxi Pi
Ruoxi Pi
CBCatherine A. Blish
Catherine A. Blish
Our understanding of protective vs. pathologic immune responses to SARS-CoV-2, the virus that causes Coronavirus disease 2019 (COVID-19), is limited by inadequate profiling of patients at the extremes of the disease severity spectrum. Here, we performed multi-omic single-cell immune profiling of 64 COVID-19 patients across the full range of disease severity, from outpatients with mild disease to fatal cases. Our transcriptomic, epigenomic, and proteomic analyses reveal widespread dysfunction of peripheral innate immunity in severe and fatal COVID-19, with the most profound disturbances including a prominent neutrophil hyperactivation signature and monocytes with anti-inflammatory features. We further demonstrate that emergency myelopoiesis is a prominent feature of fatal COVID-19. Collectively, our results reveal disease severity-associated immune phenotypes in COVID-19 and identify pathogenesis-associated pathways that are potential targets for therapeutic intervention. One Sentence Summary: Single-cell profiling demonstrates multifarious dysregulation of innate immune phenotype associated with COVID-19 severity.

13 September 2025 in iScience
Verified
Journal Article
Open access
RPRuoxi Pi
Ruoxi Pi
NZNancy Q. Zhao
Nancy Q. Zhao
ABAllison J. Bien
Allison J. Bien
TRThanmayi Ranganath
Thanmayi Ranganath
CSChristof Seiler
Christof Seiler
CBCatherine A. Blish
Catherine A. Blish
Natural killer (NK) cells respond rapidly in early HIV-1 infection. HIV-1 prevention and control strategies harnessing NK cells could be enabled by mechanistic understanding of how NK cells recognize HIV-infected T cells. Here, we profiled the phenotype of human primary NK cells responsive to autologous newly HIV-infected CD4 T cells in vitro. We characterized the patterns of NK cell ligand expression on CD4 T cells at baseline and after infection with a panel of transmitted/founder HIV-1 strains to identify key receptor-ligand pairings. CRISPR editing of CD4 T cells to knock out the NKp30 ligand B7-H6, or the NKG2D ligand MICB reduced NK cell responses to HIV-infected cells in some donors. Blockade of NKp30 or NKG2D on NK cells compromised their specificity of killing HIV-infected cells. Collectively, we identified receptor-ligand pairs including NKp30:B7-H6 and NKG2D:MICB that contribute to NK cell recognition of HIV-infected cells.

27 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NZNancy Q. Zhao
Nancy Q. Zhao
RPRuoxi Pi
Ruoxi Pi
DNDavid N. Nguyen
David N. Nguyen
TRThanmayi Ranganath
Thanmayi Ranganath
CSChristof Seiler
Christof Seiler
CBCatherine A. Blish
Catherine A. Blish
Summary: Natural killer (NK) cells respond rapidly in early HIV-1 infection. HIV-1 prevention and control strategies harnessing NK cells could be enabled by mechanistic understanding of how NK cells recognize HIV-infected T cells. Here, we profiled the phenotype of human primary NK cells responsive to autologous HIV-1-infected CD4 + T cells in vitro. We characterized the patterns of NK cell ligand expression on CD4 + T cells at baseline and after infection with a panel of transmitted/founder HIV-1 strains to identify key receptor-ligand pairings. CRISPR editing of CD4 + T cells to knockout the NKp30 ligand B7-H6, or the NKG2D ligands MICB or ULBP2 reduced NK cell responses to HIV-infected cells in some donors. In contrast, overexpression of NKp30 or NKG2D in NK cells enhanced their targeting of HIV-infected cells. Collectively, we identified receptor-ligand pairs including NKp30:B7-H6 and NKG2D:MICB/ULBP2 that contribute to NK cell recognition of HIV-infected cells.